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A patient with Menkes Kinky Hair disease was treated 
with infusions of copper-histidine which resulted in 
normal copper values in the cerebrospinal fluid. This 
tends to confirm the in vitro data that copper is trans- 
ported into the central nervous system complexed with 
histidine or other similar ligands. 
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Introduction 
M e n k e s  k inky  hai r  d i sease  ( M K H D )  is a d i so rde r  of  
impa i r ed  d ie tary  c o p p e r  abso rp t ion  and  a b n o r m a l  coppe r  
d i s t r ibu t ion  [1,2]. Pa t ien ts  p resen t  wi th  severe  deve lop -  
m e n t a l  re tardat ion ,  hypo ton ia ,  se izures ,  and  abnorma l i t i e s  
o f  c o n n e c t i v e  t i ssues  and  b l o o d  vessels .  P r io r  t r ea tmen t s  
h a v e  focused  on  co r rec t ing  the  sys temic  c o p p e r  def ic iency.  
I n t r avenous  admin i s t r a t i on  o f  inorgan ic  coppe r  salts fa i led  
to n o r m a l i z e  cen t ra l  n e r v o u s  sys tem ( C N S )  c o p p e r  mea -  
sured  in the  ce reb rosp ina l  f lu id  (CSF)  [3,4] (persona l  com-  
mun ica t ion ) .  Similar ly ,  co r rec t ion  o f  n e u r o d e v e l o p m e n t a l  
de f ic ienc ies  has  b e e n  unsuccess fu l  in  the classic ,  severe  
fo rm of  this  d i sease  [5]. Th i s  repor t  d o c u m e n t s  the  intra-  
v e n o u s  in fus ion  o f  copper -h i s t id ine  wi th  the cor rec t ion  o f  
C S F  coppe r  to no rma l  va lues  in a pa t i en t  wi th  M K H D .  
Case Report 
A 20-week-old male presented with new-onset respiratory difficulty 
and seizures. He had episodes of fine upper extremity tremors and 
apnea. His parents reported that he smiled, cooed, and could follow 
objects with his eyes, but was unable to reach, grasp, or roll over. 
The examination revealed a lethargic, extremely hypotonic, pale, cau- 
casian infant with scaly skin. The scalp felt like fine sand paper due to 
the short broken hairs and microscopic examination revealed charac- 
teristic pili torti of MKHD. Head control was extremely poor and the 
child slipped through the examiner's hands on vertical suspen- 
sion. Skull radiography revealed wormian bones. Plasma copper was 
23 mg/dl (normal: 70-130 mg/dl), ceruloplasmin 1.5 mg/dl (normal: 
15-35 mg/dt), and CSF copper 5 ng/ml (normal: 12-27 ng/ml) [4]. Cul- 
tured skin flbroblasts from the patient retained an excess of copper in a 
pattern indicative of MKHD (personal communication) [6]. 
After institutional review and parental consent, treatment with 10 
ml/kg of fresh frozen plasma (FFP) immediately followed by intra- 
venous copper-histidine was initiated. Each treatment contained 3.6 mg 
of cupric acetate monohydrate, 8.0 mg of histidine hydrochloride 
monohydrate, adjusted to pH 7.0, 10 cc in volume and normal saline 
salt concentration providing 1.2 mg of elemental copper in a molar 
ratio of copper/histidine of 1/2. The copper-histidine solution was fil- 
tered for sterility, added to 20 cc of normal saline, and infused over 1 
hour. The patient exhibited no side effects except for sclerosis of the 
veins. The parents reported that approximately 6 hours after infusions 
the patient was fussier than usual. Broviac ® catheter placement solved 
intravenous access difficulties. Therapy was monitored by serial serum 
ceruloplasmin, plasma copper, plasma zinc, and CSF copper measured 
by flame and tameless atomic absorption spectrometry. All samples 
were drawn just prior to giving the next copper dose and therefore 
represent trough levels. 
The patient initially was treated daily with FFP and intravenous cop- 
per-histidine until the plasma copper, CSF copper, and ceruloplasmin 
normalized. The child then received weekly therapy with FFP and cop- 
per-histidine. The ceruloplasmin, plasma copper, and CSF copper all 
declined, and a short period of daily treatment was reinstituted until 
values normalized (Figs 1-3). Again weekly parenteral FFP and copper- 
histidine was instituted, but this time was supplemented with daily oral 
copper-histidine, the same solution used above but without the final 
20 cc dilution. The oral dose was adjusted occasionally but was given 
to a maximum of 2 cc 3 times daily (elemental copper 0.72 mg/day 
orally). The combination of weekly parenteral and 3 times daily oral 
therapy maintained plasma and CSF copper levels in the normal range. 
On one testing an elevated CSF copper level was obtained which was 
associated with an elevated serum copper value. No abnormalities in 
liver or kidney function tests resulted from the treatment. The plasma 
zinc concentrations fluctuated greatly, but elevated copper concentra- 
tions did not consistently suppress plasma zinc concentrations. 
At 13 months of age our patient exhibited no neurodevelopmental 
gains with therapy. A Bayley test demonstrated that the child's abilities 
were the same as at the time of his diagnosis and placed the child's 
development at 1 month of age. Treatments with FFP were stopped to 
avoid the risks of transfusion-acquired disease, but weekly parenteral 
copper and daily oral copper therapy continued. Twelve weeks after 
FFP transfusions were discontinued plasma copper levels remained 
within the normal range and the CSF copper decreased to the normal 
range. 
Discussion 
The  p r ima ry  b i o c h e m i c a l  abnorma l i t i e s  in M K H D  h a v e  
b e e n  re la ted  to a b n o r m a l  c o p p e r  b i n d i n g  and  defec t ive  
coppe r  t r anspor t  at  the  in tes t ine  and  the  b lood -b ra in  bar-  
rier. CNS  man i f e s t a t i ons  o f  the d i sease  m a y  be  re la ted  to 
dys func t ion  of  the copper - requ i r ing  e n z y m e s  c y t o c h r o m e  
c [5] and  d o p a m i n e  13-hydroxylase [7]. T ranspor t  of  c o p p e r  
in to  the  C N S  has  b e e n  s tudied  us ing  rat  h y p o t h a l a m i c  
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Scattergram of CSF copper concentrations prior to and during therapy. 
tissue slices [8]. Two facilitated diffusion processes were 
elucidated. Both systems had broad ligand specificity with 
respect to amino acids (i.e., histidine, cysteine, threonine, 
glycine) and small peptides (Gly-His-Lsy and glutathione) 
but albumin did not serve as a facilatory ligand. In our 
patient intravenous administration obviated the need for 
intestinal copper absorption. The plasma and CSF copper 
values closely paralleled each other, confirming that cop- 
per was provided in a form that could be transported in the 
CNS. 
Pretreatment with FFP prior to the infusion of copper- 
histidine, when performed weekly over a period of 
months, resulted in a CSF copper value of approximately 
2 times normal. When the FFP pretreatment was discon- 
tinued the CSF copper decreased to normal values. This 
limited observation raises the possibility that there may be 
a factor in FFP that further facilitates copper accumulation 
into the CNS. 
The relationship between CSF and brain copper in this 
disease has not been reported and would require brain 
biopsies to determine it; however, in Wilson disease there 
is a relationship between CSF copper, treatment, and clini- 
cal improvement which presumably is related to a decline 
in brain copper [9]. 
Our patient should be compared with other MKHD 
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correct ion o f  C S F  copper  with copper  sulfate therapy has 
general ly  fai led and high normal  and elevated values have  
not been reported even with h igher  dose equivalents  of  
e lementa l  copper  [3,4] (personal communica t ion) .  In con- 
trast to 2 patients treated with subcutaneous copper-his-  
t idine injections,  our  patient did not  make  neurodevelop-  
mental  progress  [10]. Perhaps our t reatment  was begun  too 
late in deve lopment ,  after a cri t ical  period, so that the child 
was unable to recover.  Alternat ively,  there may  be genetic  
heterogenei ty  in M K H D  such that some patients are un- 
able to respond to copper-his t idine therapy; therefore,  al- 
though copper  reaches the CNS,  normal  neurodevelop-  
ment  may  not  occur  because the patient may  be unable to 
correct ly  utilize the copper. Genet ic  he terogenei ty  govern-  
ing the response to a different type o f  M K H D  therapy has 
been reported [4]. 
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